1. Pisani P, Parkin DM, Bray FI, Ferlay, J: Estimates of the worldwide mortality from 25 major cancers in 1990. Int J Cancer 1999; 83: 18-29.
2. Cancer Facts and Figures-2000: American Cancer Society.
3. Minna JD, Pass H, Glatstein E, Ihde DC: Lung cancer: Principles and Practice of Oncology. Edited by VT deVita, S. Rosenberg, S. Hellman. Philadelphia, J.B. Lippincott 1989, pp 591-705.
4. Harris CC: Chemical and physical carcinogenesis: advanced and perspectives. Cancer Res 1991; 51: 5023s-5044s.
5. Sozzi G, Miozzo M, Pastorino U, Pilotti S, Donghi R, Giarola M, Gregorio LD, Manenti G, Radice P, Minoletti F, Porta GD, Pierotti MA: Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesion. Cancer Res 1995; 55: 135-140.
6. Stanley LA: Molecular aspects of chemical carcinogenesis: the roles of oncogenes and tumor suppressor genes. Toxicology 1995; 96: 173-194.
7. Bishop JM: Molecular themes in oncogenes. Cell 1991; 64: 235-248.
8. Barbacid M: Ras genes. Ann Rev Biochem 1987; 56: 779-827.
9. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991; 253: 49-53.
10. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T: Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990; 5: 1037-1043.
11. Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K, Sasazuki T: ras gene mutation as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 1992; 52: 2903-2906.
12. Rodenhuis S, Slebos RJ: Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992; 52: 2665s-2669s.
13. Husgafvel-Prusiainen K, Hackman P, Ridanpaa M, Anttila S, Karjalainen A, Partanen T, Taikina-Aho O, Heikkila L, Vaino H: K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. Int J Cancer 1993; 53: 250-256.
14. Keohavong P, DeMichele MAA, Melacrinos AC, Landreneau RJ, Weyant RJ, Siegfried JM: Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res 1996; 2: 411-418.
15. Przygodzki RM, Finkelstein SD, Langer JC, Swalsky PA, Fishback N, Bakker A, Guinee DG, Koss M, Travis WD: Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors: correlation with histological subtype and clinical outcome. Am J Pathol 1996; 148: 1531-1541.
16. Bos JL: ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
17. Westra WH, Slebos RJC, Offerhaus GJA, Goodman SN, Evers SG, Kensler TW, Askin FB, Rodenhius S, Hruban RH: K-ras oncogene activation in lung adenocarcinomas from former smokers. Cancer 1993; 72: 432-438.
18. Yaremko ML, Wasylyshyn ML, Westbrook CA, Michelassi F: Oncogenes, suppressor genes, and allele losses in colon cancer. Adv Surg 1993; 26: 323-332.
19. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF: Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 1991; 6:1353-1362.
20. Siegfried JM, Gillespie TA, Mera R, Casey TJ, Keohavong P, Hunt JD: Prognostic value of specific K-ras mutations in lung adenocarcinomas. Cancer Epidemiol Biomarkers Prev 1997; 6: 841-847.
21. Thiberville L, Payne P, Vielkinds J, LeRiche J, Horsman D, Nouvet G, Palcic B, Lam S: Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. Cancer Res 1995; 55: 5133-5139.
22. Sugio K, Kishimoto Y, Virmani AK, Hung JY, Gazdar AF: K-ras mutations are relatively late event in the pathogenesis of lung carcinomas. Cancer Res 1994; 54: 5811-5815.
23. Westra WH, Baas IO, Hruban RH, Askin FB, Wilson K, Offenhaus GJA, Slebos RJC: K-ras oncogene activation in atypical alveolar hyperplasia of the human lung. Cancer Res 1996; 56: 2224-2228.
24. Li ZH, Zheng J, Weiss LM, Shibata D: c-K-ras and p53 mutations occur very early in adenocarcinomas of the lung. Am J Pathol 1994; 144: 303-309.
25. Cha RS, Zarbl H, Keohavong P, Thilly WG: Mismatch amplification mutation assay (MAMA): Application to the c-H-ras gene. PCR Method Applic 1992; 2: 14-20.
26. Jiang W, Kahn SM, Guillem JG, Lu SH, Weinstein IB: Rapid detection of ras oncogenes in human tumors: application to colon, esophageal, and gastric cancer. Oncogene 1989; 4: 923-928.
27. Kumar R, Dunn L: Designed diagnostic restriction fragment length polymorphism for the detection of point mutations in ras oncogenes. Oncogene 1989; 1: 235-241.
28. Levi S, Urbano-Ispizua A, Gill R, Thomas DM, Gilbertson J, Foster C, Marshall CJ: Multiple K-ras 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 1991; 51: 3497-3502.
29. Kahn SM, Jiang W, Culbertson TA, Weinstein IB, Williams GM, Tomita N, Ronai Z: Rapid and sensitive non-radioactive detection of mutant K-ras genes via enriched PCR amplification. Oncogene 1991; 6: 1079-1083.
30. Yakubovskaya MS, Spiegelman V, Luo FC, Malaev F, Salnew A, Zborovskaya I, Gasparian A, Polotsky B, Machaladze Z, Trachtenberg AC, Belitsky GA, Ronai Z: High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer. Int J Cancer 1995; 63: 810-814.
31. Mills NE, Fishman CL, Scholes J, Anderson SE, Rom WN, Jacobson DR: Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. J Natl Cancer Inst 1995; 87: 1056-1060.
32. Mao L, Hruban RH, Boyle JO, Tockman M, Sidransky D: Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994; 54: 1634-1637.
33. Scott FM, Modali R, Lehman TA, Seddon M, Kelly K, Dempsey EC, Wilson V, Tockman MS, Mulshine JL: High frequency of K-ras codon 12 mutations in bronchoalveolar lavage fluid of patients at high risk for second primary lung cancer. Clin Cancer Res 1997; 3: 479-482.
34. Keohavong P, Zhu D, Whiteside TL, Swalsky P, Bakker A, Elder EM, Siegfried JM, Srivastava S, Finkelstein SD: Detection of infrequent and multiple K-ras mutations in human tumors and tumor-adjacent tissues. Anal Biochem 1997; 247: 394-403.
35. Keohavong P, Mady, HH, Gao WM, Siegfried JM, Luketich JD, Melhem MF: Topographic analysis of K-ras mutations in histologically normal lung tissues and tumors of lung cancer patients. Br J Cancer 2001; 85: 235-241.
36. Pretlow TP, Barrow BJ, Ashton WS, O'Riordan MA, Pretlow TG, Jurcisek JA, Stellato TA: Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 1991; 51: 1564-1567.
37. Minamoto T, Yamashita N, Ochiai A, Mai M, Sugimura T, Ronai Z, Esumi H: Mutant K-ras in apparently normal mucosa of colorectal cancer patients. Its potential as a biomarker of colorectal tumorigenesis. Cancer 1995; 75: 1520-1526.
38. Zhu D, Keohavong P, Finkelstein SD, Swalska P, Bakker A, Weissfeld J, Srivastava S, Whiteside TL: K-ras mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients. Cancer Res 1997; 57: 2485-2492.
39. Yanagisawa A, Ohtake K, Ohashi K, Hori M, Kitagawa T, Sugano H, Kato Y: Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 1993; 53: 953-956.
40. Berthelemy P, Bouisson M, Escourrou J, Vaysse N, Rumeau JL, Pradayrol L: Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer. Ann Intern Med 1995; 123: 188-191.
41. Brentnall TA, Chen R, Lee JG, Kimmey MB, Bronner MP, Haggitt RC, Kowdley KV, Hecker LM, Byrd DR: Microsatellite instability and K-ras mutations associated with pancreatic adenocarcinoma and pancreatitis. Cancer Res, 1995; 55: 4264-4267.
42. Tada M, Ohashi M, Shiratori Y, Okudaira T, Komatsu Y, Kawabe T, Yoshida H, Machinami R, Kishi K, Omata M: Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 1996; 110: 227-231.
43. Wilentz RE, Chung CH, Sturm PD, Musler A, Sohn TA, Offerhaus GJ, Yeo CJ, Hruban RH, Slebos RJ: K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer 1998; 82: 96-103.
44. Santos E, Martin-Zanca D, Reddy EP, Pierotti MA, Della Porta G, Barbacid M: Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 1984; 223: 661-664.
45. Urban T, Ricci S, Lacave R, Antoine M, Kambouchner M, Capron F, Bernaudin JF: Codon 12 Ki-ras mutation in non-small-cell lung cancer: comparative evaluation in tumoural and non-tumoural lung. Br J Cancer 1996: 74:1051-1055.
46. Clements NC, Nelson MA, Wymer JA, Savage C, Aguirre M, Garewal S: Analysis of K-ras gene mutations in malignant and nonmalignant endobronchial tissue obtained by fiberoptic bronchoscopy. Am J Respir Crit Care Med 1995; 152: 1374-1378.
47. Urban T, Ricci S, Danel C, Antoine M, Kambouchner M, Godard V, Lacave R, Bernaudin JF: Detection of codon 12 K-ras mutations in non-neoplastic mucosa from bronchial carina in patients with lung cancer. Br J Cancer 2000; 82: 412-417.
48. Slaughter D, Southwick H, Smejkal W: “Field cancerization” in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953; 6: 953-968.
49. Strong MS, Incze J, Vaughan CW: Field cancerization in the aerodigestive tract: its etiology, manifestation, and significance. J Ontolaryngol 1984; 13: 1-6.
